NCT02932007 Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 40 participants in total. It began in 2017-03-28 with a primary completion date of 2020-03.

Brief Summary

The goal of this pilot study is to explore the efficacy of chloroquine in terminating persistent AF and assess its potential role as a pharmacological cardioversion agent for the management of AF.

Eligibility Criteria

Inclusion Criteria: 1. Age 18 years and older 2. History of symptomatic persistent AF Persistent AF - defined as continuous AF that is sustained more than 7 days but less than 12 months. Episodes of AF of ≥ 48 hours duration in which a decision is made to terminate with electrical or pharmacological cardioversion prior to 7 days will also be classified as persistent AF 3. AF must be documented at least once either by ECG, event monitoring, loop recorder, telemetry, trans-telephonic monitoring, pacemaker or cardiac defibrillator readouts within 24 months prior to enrollment 4. Currently on anticoagulation therapy as indicated per local guidelines, which is considered optimal for stroke prevention in the opinion of the investigator 5. Implanted dual chamber pacemaker/ICD capable of monitoring atrial arrhythmias or willingness to wear a 2 weeks event monitor if patient does not have a device capable of monitoring atrial arrhythmias 6. Signed informed consent Exclusion Criteria: 1. Age \< 18 years 2. AF felt to be secondary to an obvious reversible cause such as, but not limited to, acute myocardial infarction, pulmonary embolism, recent surgery, pericarditis, alcohol intoxication, hypoxemia, or thyrotoxicosis 3. Structural heart disease including patients with artificial heart valves or valvular AF 4. Obstructive coronary artery disease or history of any myocardial infarction 5. Ejection fraction \< 50% within 1 year of consent 6. Severe or moderate to severe aortic stenosis, mitral stenosis, aortic regurgitation, or mitral regurgitation per PI discretion 7. Prolonged QTc of \>460 msec on baseline ECG 8. Contraindications to quinolines 9. Known allergy or hypersensitivity to Chloroquine 10. Use of amiodarone 12 months prior to enrollment 11. History of AF ablation within 30 days prior to enrollment 12. Renal impairment (eGFR \< 30 mL/min/1.73 m2 or Serum Creatinine \> 1.25 mg/dL) for subjects over the age of 65 13. Hepatic disease (ALT/AST 2X the upper normal limit) 14. History of alcohol abuse and/or drug abuse per PI discretion 15. Pre-existing auditory damage 16. History of epilepsy 17. Women of child-bearing potential (those who have had a menstrual period in the previous 12 months) who: * are pregnant or breast-feeding or plan to become pregnant during study or * who are not surgically sterile and are not practicing two acceptable methods of birth control, or do not plan to continue practicing two acceptable methods of birth control throughout the study (highly effective methods are listed under section 6.0 Pregnancy) 18. Current participation in another clinical study 19. Serious or active medical or psychiatric condition which, in the opinion of the investigator, may interfere with treatment, assessment, or compliance with the protocol 20. Not able to discontinue medications known to have significant interactions with chloroquine

Contact & Investigator

Frequently Asked Questions

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.